Mallinckrodt (MNK) Commences Phase III Study Of StrataGraft
Zacks Investment Research | Jun 07, 2017 11:09PM ET
Mallinckrodt plc (NYSE:MNK) has enrolled the first patient in phase III study, assessing StrataGraft regenerative skin tissue for promoting autologous skin regeneration in patients with thermal burns.
The company’s share price decreased 19.7% year to date compared with the Zacks classified Medical – Generics Drugs industry’s decline of 6.7%.
The phase III study will include patients with 3-49% of complex skin defects on their total body surface area due to thermal burns with dermal elements intact. Excision and autografting are clinically indicated to treat the burns.
The company is working with the United States Biomedical Advanced Research and Development Authority (BARDA), supporting the StrataGraft development.
We remind investors that Mallinckrodt added StrataGraft to its portfolio through acquisition of Stratatech Corporation, a privately held regenerative medicine company, focused on developing unique, proprietary skin substitute products in August last year.
The FDA had granted an orphan product status to StrataGraft in 2012. Upon a potential approval, StrataGraft could be the first biological "off-the-shelf" skin substitute product for treatment of severe burns.
Every year, approximately 10,000 patients in the U.S. are hospitalized for the treatment of severe burns and the market for skin graft products used in this application is estimated to be approximately $300 million in the country.
Zacks Rank and Stocks to Consider
Mallinckrodt carries a Zacks Rank #3 (Hold). Some better ranked stocks in health care sector include VIVUS, Inc. (NASDAQ:VVUS) , MEI Pharma, Inc. (NASDAQ:MEIP) and Aeglea BioTherapeutics (NASDAQ:AGLE) . While VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy), Aeglea carries a Zacks Rank #2 (Buy). You can see .
VIVUS’ loss per share estimates narrowed from 502 cents to 39 cents for 2017 over the ast 60 days. The company posted positive earnings surprises in all four trailing quarters, with an average beat of 233.69%. The share price of the company increased 12.2% year to date.
MEI Pharma’s estimates reduced from loss per share of 1 cent to gain per share of the same for 2017, over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with average beat of 66.56%. The share price of the company increased 37.5% year to date.
Get The News You Want
Aeglea’s loss per share estimates narrowed from $3.64 to $2.48 for 2017 over last 60 days. The company posted positive earnings surprises in three of four trailing quarters, with average beat of 20.75%.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy... Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early.Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.